{
    "nctId": "NCT06145399",
    "briefTitle": "A Study of 1 8F-FDHT PET/MRIScans in Women With Breast Cancer",
    "officialTitle": "[18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone PET Imaging In Patients Advanced Breast Cancer",
    "overallStatus": "WITHDRAWN",
    "conditions": "Breast Cancer, Breast Carcinoma, Metastatic Breast Cancer, Metastatic Breast Carcinoma, Female Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "EARLY_PHASE1",
    "allocation": "NA",
    "primaryPurpose": "DIAGNOSTIC",
    "enrollmentCount": 0,
    "primaryOutcomeMeasure": "Number of lesions that correlate 18F-FDHT uptake with IHC expression of AR",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Age \u2265 18 years\n* ECOG performance score of 0-2\n* Signed informed consent\n* Histologically confirmed AR+ breast cancer\n\n  * All participants under consideration for enrollment will have their tumor specimen tested centrally at MSK; nuclear AR staining \u2265 1% will be considered positive.\n* Progressive metastatic breast cancer manifested as increase in evaluable disease OR the appearance of new sites of disease since the date of the last imaging study performed and under consideration for AR-targeted therapy\n* Planning to undergo treatment with agents targeting the antiandrogen signaling pathway on a clinical trial\n\nExclusion Criteria:\n\n* Life expectancy \\< 3 months\n* Pregnancy or lactation\n* Participants who cannot undergo scanning because of\n\n  * weight limits\n  * devices or implants that are not MRI safe\n  * allergies to contrast materials\n* CNS only disease on recent imaging",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}